Transcranial Magnetic Stimulation for Alzheimer's Disease
Neuromodulation of Brain Function in Alzheimer's Disease and Related Dementias
This study is testing if a new brain stimulation treatment can help improve memory and brain function in older adults and those with mild cognitive impairment.
Quick facts
| Phase | Early Phase 1 |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 40 Years to 99 Years |
| Sex | All |
| Sponsor | Massachusetts General Hospital Academic / other |
| Locations | 1 site (Boston, Massachusetts) |
| Trial ID | NCT06538311 on ClinicalTrials.gov |
What this trial studies
This study investigates the effects of repetitive Transcranial Magnetic Stimulation (rTMS) on memory and brain function in older adults and patients with mild cognitive impairment. Participants will undergo a series of rTMS sessions over a two-week period, with evaluations before and after the treatment to assess changes in cognitive abilities and brain imaging. The goal is to understand how non-invasive brain stimulation can influence memory-related brain activity.
Who should consider this trial
Good fit: Ideal candidates include individuals aged 40-99 with mild cognitive impairment, logopenic progressive aphasia, or those who are cognitively unimpaired but at risk for Alzheimer's disease.
Not a fit: Patients with significant neurological or psychiatric conditions, or those with contraindications to MRI, may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could improve memory function and cognitive health in patients with early signs of Alzheimer's disease and related conditions.
How similar studies have performed: Previous studies using rTMS have shown promise in improving cognitive function, suggesting potential for success in this novel application for Alzheimer's disease.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Between the ages of 40-99 2. Native English speakers 3. Willing and able to consent to the protocol and undergo imaging and neuropsychological testing at the specified time points 4. Patients with PPA will be asked to bring a study partner to all visits 5. Patients with very mild or mild PPA, patients with amnestic mild cognitive impairment and cognitively unimpaired participants with preclinical AD will be included. Exclusion Criteria: 1. History of head trauma involving loss of consciousness or alteration in consciousness 2. Another major neurologic or psychiatric condition 3. Known presence of a structural brain lesion (e.g. tumor, cortical infarct) 4. Any contraindication to MRI, such as presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments, or foreign objects in the eyes, skin, or body 5. Longstanding premorbid history (i.e. longer than 10 years) of alcohol or substance abuse with continuous abuse up to and including the time that the symptoms leading to clinical presentation developed 6. Any significant systemic illness or unstable medical condition which could lead to difficulty complying with the study protocol. 7. Unwilling to return for follow-up, undergo neuropsychological testing, TMS, and MR imaging 8. History of unprovoked seizures (i.e., seizures that occur in the absence of a clear provocation such as hyponatremia, hypoglycemia, etc.). 9. Subjects who have a first degree relative (e.g., father, mother or sibling) with a seizure disorder. 10. Subjects currently taking, or plan to take, medications which are highly epileptogenic. These include: clozapine, high doses of bupropion (i.e., greater than 400mg daily), diphenhydramine, cyclosporine, isoniazid, imipenem, chloroquine, tramadol and theophylline. 11. Subjects actively on anti-amyloid treatments. This is because they are at risk for bleeding due to amyloid-related imaging abnormalities (ARIA) that could provoke seizures.
Where this trial is running
Boston, Massachusetts
- Massachusetts General Hospital — Boston, Massachusetts, United States (Recruiting)
Study contacts
- Study coordinator: Alexandra Touroutoglou, PhD
- Email: atouroutoglou@mgh.harvard.edu
- Phone: 6176436348
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.